Aquestive Therapeutics reported first quarter 2026 revenue of $14.4 million, a 66% increase from the prior year, and a net loss per share of $0.07. The company ended the quarter with $110.7 million in cash and cash equivalents and reaffirmed its full-year 2026 guidance.
Key Highlights
- First quarter revenue grew 66% year-over-year to $14.4 million, driven by a significant increase in license and royalty revenue to $5.4 million from $0.8 million in the prior year.
- The company reaffirmed its guidance to resubmit the New Drug Application (NDA) for its epinephrine sublingual film, Anaphylm, in the third quarter of 2026.
- Aquestive secured a new five-year debt facility of up to $150 million with Oaktree Capital Management, refinancing existing debt and extending its cash runway to support the potential launch of Anaphylm.